Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification.
10.1097/CM9.0000000000001184
- Author:
Zhi-Mei ZHAO
1
;
Song-Ping WANG
;
Lei SUN
;
You-Xin JI
Author Information
1. Department of Oncology, Qingdao Central Hospital, Qingdao University, Qingdao, Shandong 266042, China.
- Publication Type:Journal Article
- MeSH:
Acrylamides;
Aniline Compounds;
Carcinoma, Non-Small-Cell Lung/genetics*;
Crizotinib/therapeutic use*;
Drug Resistance, Neoplasm/genetics*;
Erlotinib Hydrochloride/therapeutic use*;
Humans;
Lung Neoplasms/genetics*;
Mutation;
Protein Kinase Inhibitors/therapeutic use*;
Proto-Oncogene Proteins c-met/genetics*
- From:
Chinese Medical Journal
2020;134(3):373-374
- CountryChina
- Language:English
